SuperTrans Medical Overview
SuperTrans Medical is a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multidrug-resistant bacteria often known as superbugs. The companys guanidinium-rich molecular transporter (GR-MoTr) technology used in conjunction with existing FDA-approved antibiotics results in superior antimicrobial properties. SuperTrans Medical is committed to an expedited development program and a shorter path to the clinic.
Cumulative Funding Raised Over Time ($)
$2.0MApr 2020
Latest News
growth-positive
SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria
SuperTrans Medical has announced that the U.S. National Institutes of Health (NIH) will be supporting additional development efforts of its lead clinical candidate, STM-001. The support from the NIH will serve to further strengthen existing pre-clinical efficacy data for STM-001, a precision antimicrobial therapeutic being developed to combat antibiotic-resistant bacterial infections. The drug is set to enter a Phase 1 clinical trial in Australia in H1 2022. SuperTrans Medicals Intelligent RepurposingTM strategy aims to retarget commonly used antibiotics to generate highly meaningful therapeutics. The company is committed to an expedited development program and has a biotech R&D hub in Ness Ziona, Israel.
Investment
growth-positive
SuperTrans Medical appoints Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria
SuperTrans Medical has appointed three Australian companies as key clinical research partners for an upcoming clinical drug trial. The trial aims to combat antimicrobial resistance (AMR) and develop a new antibiotic. The appointed companies, CMAX, Avance Clinical, and Agilex Biolabs, will conduct Phase 1 human clinical trials in Australia in 2021. SuperTrans Medicals patented Intelligent Repurposing™ technology will be used in the drug, which involves attaching a permeator unit to an existing antibiotic to enhance its effectiveness against bacterial pathogens. The company plans to begin clinical trials for complicated Urinary Tract Infections (cUTIs) later this year. The trial is expected to take place in Adelaide, Australia.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2M |
| Last funding | $2M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.supertrans-medical.com/site/content/ |
Locations
Pinhas Sapir Street 3, Ness Ziona, Israel
525 Collins Street, Melbourne VIC 3000, Australia
Photos & Videos
No files yet
SuperTrans Medical Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (8)
biotechnologybiopharmaceuticaloncologypharmaceuticalsdrug-discoverytherapeuticsdrug-deliveryantibioticsGeographic Markets
GlobalSuperTrans Medical Financials
$2M
Total funding
Undisclosed
Capital raised
$2M
Last funding
Seed
Funding stage
1
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$2.0MApr 2020
Private Equity Funding
Undisclosed Round
Apr 2020
$2M
Mediforum Pharm (Lead)
SuperTrans Medical Lifecycle
Cumulative Funding Raised Over Time
$2.0MApr 2020
All Events
Undisclosed Round
Apr 2020
$2M
Mediforum Pharm (Lead)
SuperTrans Medical News
2 articles
growth-positive
SuperTrans Medical supported by U.S. National Institutes of Health (NIH) in developing its lead antibiotic against urgent threat drug resistant bacteria
SuperTrans Medical has announced that the U.S. National Institutes of Health (NIH) will be supporting additional development efforts of its lead clinical candidate, STM-001. The support from the NIH will serve to further strengthen existing pre-clinical efficacy data for STM-001, a precision antimicrobial therapeutic being developed to combat antibiotic-resistant bacterial infections. The drug is set to enter a Phase 1 clinical trial in Australia in H1 2022. SuperTrans Medicals Intelligent RepurposingTM strategy aims to retarget commonly used antibiotics to generate highly meaningful therapeutics. The company is committed to an expedited development program and has a biotech R&D hub in Ness Ziona, Israel.
Investment
growth-positive
SuperTrans Medical appoints Australian partners to provide crucial clinical research in the battle against drug-resistant bacteria
SuperTrans Medical has appointed three Australian companies as key clinical research partners for an upcoming clinical drug trial. The trial aims to combat antimicrobial resistance (AMR) and develop a new antibiotic. The appointed companies, CMAX, Avance Clinical, and Agilex Biolabs, will conduct Phase 1 human clinical trials in Australia in 2021. SuperTrans Medicals patented Intelligent Repurposing™ technology will be used in the drug, which involves attaching a permeator unit to an existing antibiotic to enhance its effectiveness against bacterial pathogens. The company plans to begin clinical trials for complicated Urinary Tract Infections (cUTIs) later this year. The trial is expected to take place in Adelaide, Australia.
Partners
Employee Info
| Employees (range) | 1-10 |
| Exact count | 6 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
SuperTrans Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | video or image, markets |
| BI Verification | Yotam Maman |
| Registrar ID | 516034311 |
| Crunchbase | supertrans-medical |
| Phone | +97289239102 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-15T00:00:00.000Z |
| Created | 2020-04-09T00:00:00.000Z |
| Claimed | Yes |